Evaluation of PDE4 inhibition for COPD.

Document Type

Article

Publication Date

2006

Abstract

Targeting type 4 phosphodiesterase (PDE4) for treatment of COPD has multilevel benefits to patients by reducing inflammation, relieving bronchoconstriction, and improving pulmonary circulation. The isoenzyme-specific narrow spectrum PDE4 inhibitors such as cilomilast and roflumilast may have limited clinical efficacy in managing severe and very severe COPD. Development of dual therapy by combining PDE4 inhibition with Ca2+ channel antagonism may introduce an effective novel armory for physicians to manage patients with severe COPD.

Publication Title

International journal of chronic obstructive pulmonary disease

Volume

1

Issue

4

First Page

373

Last Page

379

Comments

This article was published in International journal of chronic obstructive pulmonary disease, Volume 1, Issue 4, Pages 373-379.

The published version is available at http://www.dovepress.com/evaluation-of-pde4-inhibition-for-copd-peer-reviewed-article-COPD.

Copyright © 2006 Dove.

This document is currently not available here.

COinS